RE:VidaCare Sells for 263 MILLION. In a market created by Pyng mwjacobs wrote:
The news has posted that VidaCare, an Intraosseous Infusion device that is a direct competitor to Pyng has sold to Flextrol for $262.5 Million or approximatley 4 times annual sales.
Pyng Medical, which created the modern I/O market and was the first product to receive FDA approval, today trade at about 4 CENTS per share, with sales volumes that have reached only $5 million per year.
Our market cap at 23 million shares is less than 1 million and there are no indications that we will see any increase in this stock under present direction.
If Pyng were to sell at 4 times sales or $20 Million approximatley that would be about 90 cents per share. Is it not about time that shareholders stood up and dealt with this situation and let management know that we are very unhappy with their approach?